The application of targeted therapies in oncology continues to expand, offering more precise and effective treatment options for a wider range of cancers. Olaparib, a potent PARP inhibitor, has shown significant promise in treating certain types of prostate and pancreatic cancers, particularly those with specific DNA repair gene mutations. In prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), Olaparib is indicated for patients whose tumors harbor specific homologous recombination repair (HRR) gene mutations, including BRCA1 and BRCA2. By targeting these mutations, Olaparib offers a personalized treatment approach that can improve outcomes for a subset of patients who might not respond as well to traditional therapies. Its use in combination with other agents is also being explored to enhance efficacy. For pancreatic cancer, Olaparib has demonstrated value as a maintenance therapy. Specifically, for patients with metastatic pancreatic adenocarcinoma and germline BRCA mutations who have shown a response to first-line platinum-based chemotherapy, Olaparib can help prolong disease control. This application highlights the critical importance of genetic testing in identifying patients who are most likely to benefit from PARP inhibitor therapy. The availability of Olaparib from reputable manufacturers in China ensures that this advanced therapeutic agent can be supplied globally, supporting research and clinical applications. As the understanding of DNA repair mechanisms and their role in cancer progression deepens, Olaparib's utility in these complex cancers is likely to grow. We are committed to providing high-quality Olaparib to facilitate these advancements in cancer care, offering a reliable source for this essential pharmaceutical intermediate.